FDA and EU - Complaint E-Signatures: Documents and Review Workflow in eQMS Software Formwork
Dr. Oliver Eidel
·
Clinical Evaluation
·
Published May 24, 2022
Sending documents out for review is a crucial step for medical device compliance. Most importantly, if you're planning to enter the US market, the FDA has additional requirements for compliant e-signatures.
Watch this video to learn how eQMS software helps you automate this, saving you lots of time in the process.
Are you interested in shipping your medical software faster? Check out Formwork:
https://openregulatory.com/
Watch this video to learn how eQMS software helps you automate this, saving you lots of time in the process.
Are you interested in shipping your medical software faster? Check out Formwork:
https://openregulatory.com/
Keep watching
All videos
Automate Your Medical Device Risk Management With Formwork, An eQMS (ISO 14971 Compliance)
Dr. Oliver Eidel
440 views
·
about 4 years ago
ISO 13485 - Compliant Handling Of Records, Save Time Using OpenRegulatory Templates
Dr. Oliver Eidel
281 views
·
about 4 years ago
AI-Assisted Writing of Technical Documentation
Dr. Oliver Eidel
8.8 K views
·
over 3 years ago
I’m a medical doctor, software engineer and regulatory dude. I’m also the founder of OpenRegulatory.
Through OpenRegulatory, I’ve helped 100+ companies with their medical device compliance. While it’s also my job that we stay profitable, I try to dedicate a lot of my time towards writing free content like our articles and templates. Maybe that will make consulting unnecessary some day? :)
If you’re still lost and have further questions, reach out any time!
Through OpenRegulatory, I’ve helped 100+ companies with their medical device compliance. While it’s also my job that we stay profitable, I try to dedicate a lot of my time towards writing free content like our articles and templates. Maybe that will make consulting unnecessary some day? :)
If you’re still lost and have further questions, reach out any time!
Join the discussion. Leave a comment. Guest comments are welcome — add your email to get reply notifications.
No comments yet. Be the first to share your thoughts.